
Cassava Sciences Addresses Leaked Internal CUNY Report
Cassava Sciences, a biotechnology company focused on Alzheimer's disease, has responded to a leaked internal report from City University of New York (CUNY) that alleged research misconduct. The report found no evidence of data manipulation but cited internal record-keeping failures at CUNY. Cassava Sciences denies any involvement in CUNY's investigation and asserts confidence in the science behind their lead drug candidate, simufilam. The company's Phase 3 clinical program will continue. The leak of the report was preceded by a significant increase in short selling activity against Cassava Sciences.

